Arterial hypertension

Mrowka, Ralf

doi:10.1111/apha.12855

Cited by 4 publications

(4 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The need to combat AH is due to the fact that it is one of the leading causes of disability and death. Prolonged increase in blood pressure leads to damage to target organs and the development of cardiovascular complications -heart failure, myocardial infarction, brain stroke cerebral stroke and kidney failure [4][5][6]. The main indicator of treatment effectiveness of AH is the achievement and maintenance of disease control (achievement of the target blood pressure level).…”

Section: Introductionmentioning

confidence: 99%

Efficacy of "Kardiovitin" in integrated treatment in arterial hypertension patients

et al. 2020

View full text Add to dashboard Cite

Arterial hypertension is one of the most spread chronic non-specific human diseases and according to World Health Organization, is due to 30% of all-death outcomes in general. The aim of this study was to investigate the efficacy of Kardiovitin in the integrated treatment of arterial hypertension. Methods. A total of twenty patients took part in the study - seventeen women (average age – 64.5±8.7 years, average weight – 77.8±11.4 kg) and three men (average age – 54.6±12.4 years, average weight – 114±402 kg). A questionnaire, anamnesis, study of risk factors for hypertension, ECG, general blood analysis, general urine analysis, biochemical blood tests, were included in the examination program before and after treatment. Statistical processing was carried out with the program “Statistica 6.0”. Differences at p<0.05 were considered statistically significant. Results. It was observed a statistically significant decrease in systolic blood pressure - 120.0 (120.0-130.0) at p<0.05, in total cholesterol – 5.6 (4.6-6.4), LDL cholesterol – 3.2 (3.1-3.5) at p<0.05 after 2 months Kardiovitin therapy in addition to the standard hypotensive therapy. Conclusion. The results of the study indicate the efficacy of including Kardiovitin in the scheme for basic antihypertensive therapy as a source of bioflavonoids involved in the stabilization of the vascular wall.

show abstract

Section: Introductionmentioning

confidence: 99%

Efficacy of "Kardiovitin" in integrated treatment in arterial hypertension patients

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Sympathetic activity is enhanced in hypertension [1,2], chronic heart failure [3,4], and chronic kidney disease [5,6]. Excessive sympathetic activation contributes greatly to the occurrence and development of hypertension and related organ damage [7].…”

Section: Introductionmentioning

confidence: 99%

Chemical Stimulation of Renal Tissue Induces Sympathetic Activation and a Pressor Response via the Paraventricular Nucleus in Rats

Qiu

Zhang

et al. 2019

Neurosci. Bull.

View full text Add to dashboard Cite

Sympathetic activation and the kidney play critical roles in hypertension and chronic heart failure. The role of the kidney in sympathetic activation is still not well known. In this study, we revealed an excitatory renal reflex (ERR) in rats induced by chemical stimulation of the kidney that regulated sympathetic activity and blood pressure. The ERR was induced by renal infusion of capsaicin, and evaluated by the changes in renal sympathetic outflow, blood pressure, and heart rate. Renal infusion of capsaicin dose-dependently increased the contralateral renal sympathetic nerve activity, mean arterial pressure, and heart rate. Capsaicin in the corticomedullary border had greater effects than in the cortex or medulla. Intravenous infusion of capsaicin had no significant effects. The effects of renal infusion of capsaicin were abolished by ipsilateral renal denervation, but were not affected by bilateral sinoaortic denervation. Renal infusion of capsaicin increased the ipsilateral renal afferent activity. The ERR was also induced by renal infusion of bradykinin, adenosine, and angiotensin II, but not by ATP. Renal infusion of capsaicin increased c-Fos expression in the paraventricular nucleus (PVN) of hypothalamus. Lesion of neurons in the PVN with kainic acid abolished the capsaicin-induced ERR. These findings indicate that chemical stimulation of kidney causes an excitatory reflex, leading to sympathetic activation, pressor response, and accelerated heart rate. The PVN is an important central nucleus in the pathway of the ERR.

show abstract

“…The data of numerous clinical and experimental studies and observations suggest that the nephroprotective effect is more pronounced in angiotensin converting enzyme (ACE) inhibitors and angiotensin II receptor antagonists, in contrast to other antihypertensive drugs [3]. However, the results of recent studies, which confirmed that bradykinin, the degradation of which is blocked by ACE inhibitors, does not make a significant contribution to the systemic hemodynamic effects caused by ACE inhibitors, it becomes clear that there is a tendency to identify the systemic cardiovascular effects of ACE inhibitors and angiotensin II receptor antagonists [4].…”

mentioning

confidence: 99%

Endothelium-dependent mechanisms of nephroprotective effect of renin-angiotensin system modulators in patients with essential hypertension

Kulynych

Glavatskiy

Sychov

et al. 2020

J Educ Health Sport

View full text Add to dashboard Cite

Introduction. It has been shown that essential hypertension (EH) is one of the main causes of end-stage renal failure in 10-30% of patients on programmed hemodialysis. At the same time, according to some clinical studies, it was shown that the most widely used drugs (diuretics, beta-blockers, calcium channel antagonists, etc.) effectively reduce high blood pressure (BP), are able to prevent the development of myocardial infarction and cerebral catastrophes, however, do not have a sufficient nephroprotective effect. The aim of the study is to identify the nephroprotective efficacy of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists in patients with EH. Materials and methods of research. To achieve this goal, 40 patients with stage I-II EH with a level of I-III degree of arterial hypertension at the age of 34 to 63 years (mean age 45.8±1.14

show abstract

Arterial hypertension

Cited by 4 publications

References 17 publications

Efficacy of "Kardiovitin" in integrated treatment in arterial hypertension patients

Efficacy of "Kardiovitin" in integrated treatment in arterial hypertension patients

Chemical Stimulation of Renal Tissue Induces Sympathetic Activation and a Pressor Response via the Paraventricular Nucleus in Rats

Endothelium-dependent mechanisms of nephroprotective effect of renin-angiotensin system modulators in patients with essential hypertension

Contact Info

Product

Resources

About